SCHEMBL17685281

SCHEMBL17685281

Cc1cnc(Nc2ccc(S(N)(=O)=O)cc2)nc1Nc1cccc(CNS(=O)(=O)N(C)C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 11/20 0.56
PTK2 Q05397 4/20 0.56
EGFR P00533 4/20 0.56
BTK Q06187 3/20 0.56
SYK P43405 3/20 0.56
NTRK1 P04629 2/20 0.56
ITK Q08881 2/20 0.56
CDK2 P24941 2/20 0.56
CDC7 O00311 1/20 0.56
PLK4 O00444 1/20 0.56
CHEK1 O14757 1/20 0.56
AURKA O14965 1/20 0.56
DCLK1 O15075 1/20 0.56
PDPK1 O15530 1/20 0.56
DAPK3 O43293 1/20 0.56
JAK2 O60674 1/20 0.56
ROCK2 O75116 1/20 0.56
MAP4K4 O95819 1/20 0.56
PAK4 O96013 1/20 0.56
CHEK2 O96017 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17685307 0.94 JAK3 (0.59) JAK3PTK2EGFRBTKSYK
SCHEMBL17685258 0.91 EGFR (0.51) JAK3PTK2EGFRBTKSYK
SCHEMBL2471890 0.91 JAK3 (0.63) JAK3PTK2EGFRBTKSYK
SCHEMBL2470647 0.91 CDK2 (0.53) JAK3PTK2EGFRBTKSYK
SCHEMBL2474786 0.88 JAK3 (0.56) JAK3PTK2EGFRBTKSYK
SCHEMBL4971147 0.86 JAK3 (0.56) JAK3PTK2EGFRBTKSYK
SCHEMBL2475802 0.81 JAK3 (0.60) JAK3PTK2EGFRBTKSYK
SCHEMBL2475718 0.81 NTRK1 (0.60) JAK3PTK2EGFRBTKSYK
SCHEMBL4973975 0.81 JAK3 (0.55) JAK3PTK2EGFRBTKSYK
SCHEMBL2474254 0.80 NTRK1 (0.56) PTK2NTRK1CDK2AURKACDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370415-B1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS INC (US) 2016-04-20 EP claimed
EP-2370415-B1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS INC (US) 2016-04-20 EP disclosed